NC
ICPT

Nexthera Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Nexthera Capital’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$12.1M Buy
152,441
+140,489
+1,175% +$12.6M 10.1% 1
2019
Q1 		$1.34M Buy
+11,952
New +$1.31M 1.62% 18

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Nexthera Capital's ICPT Position: Q2 2019 in Review

Nexthera Capital increased its Intercept Pharmaceuticals, Inc. (ICPT) stake by 1,175% in Q2 2019, buying an estimated $12.6M and bringing the position to 152,441 shares worth $12.1M. The position accounts for 10.1% of the portfolio, ranked #1.

Nexthera Capital first reported a position in ICPT in Q1 2019 and has held it in 2 quarters since. 196 funds tracked by Wall St. Rank hold ICPT as of Q2 2019.

  • Nexthera Capital held 152,441 shares of Intercept Pharmaceuticals, Inc. worth $12.1M as of Q2 2019.
  • Nexthera Capital bought 140,489 Intercept Pharmaceuticals, Inc. shares in Q2 2019, an estimated $12.6M.
  • Intercept Pharmaceuticals, Inc. made up 10.1% of Nexthera Capital's portfolio in Q2 2019, its #1 holding.
  • Nexthera Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2019 and has held it in 2 quarters since.
  • 196 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2019.

Based on Nexthera Capital's 13F filing for Q2 2019, filed 14 Aug 2019.